Sutro Biopharma, Inc.
HealthcareNASDAQ:STRO · NASDAQ Global Market
+$2.32 today
Vol 0.15M · Avg 0.27M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$99.6M of revenue converted into -$153.6M of net income for the selected period. Gross margin is 97.8% and net margin is -317.8%, showing how much revenue survives after costs and taxes. EPS is $-307.72, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $102.5M +65.2% | $62.0M -59.6% | $153.7M +126.8% | $67.8M +9.5% | $61.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $7.3M +1.5% | $7.2M +5.9% | $6.8M -17.8% | $8.3M -15.2% | $9.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $95.2M +73.6% | $54.8M -62.7% | $146.9M +147.0% | $59.5M +14.2% | $52.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 92.9% +4.5pp | 88.4% -7.2pp | 95.6% +7.8pp | 87.8% +3.6pp | 84.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $166.4M -34.0% | $252.0M +39.7% | $180.4M +31.5% | $137.2M +31.4% | $104.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $41.0M -15.3% | $48.5M -22.6% | $62.6M +5.1% | $59.5M +6.3% | $56.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $200.1M -31.8% | $293.3M +24.2% | $236.2M +25.3% | $188.4M +25.1% | $150.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $7.3M +1.5% | $7.2M +5.9% | $6.8M -17.8% | $8.3M +71.1% | $4.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$145.6M +19.3% | -$180.5M -165.7% | -$67.9M +35.4% | -$105.1M -7.7% | -$97.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -142.1% +148.7pp | -290.9% -246.7pp | -44.2% +110.9pp | -155.0% +2.6pp | -157.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$105.0M +56.0% | -$238.5M -167.1% | -$89.3M +30.8% | -$128.9M -30.9% | -$98.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -102.4% +281.9pp | -384.3% -326.3pp | -58.1% +132.2pp | -190.3% -31.0pp | -159.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $9.3M -79.2% | $44.4M +206.2% | $14.5M +320.0% | $3.5M +498.8% | $577.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $38.2M +23.0% | $31.1M +30.8% | $23.8M +609.8% | $3.3M +6.7% | $3.1M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$86.2M -745.7% | $13.4M +1872.7% | $677.0K -94.5% | $12.2M +274.5% | -$7.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$191.2M +15.1% | -$225.1M -154.1% | -$88.6M +24.1% | -$116.7M -10.6% | -$105.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -186.5% +176.3pp | -362.8% -305.2pp | -57.6% +114.6pp | -172.2% -1.6pp | -170.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$93.0K -103.9% | $2.4M -87.0% | $18.2M +627.7% | $2.5M | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$191.1M +16.0% | -$227.5M -113.0% | -$106.8M +10.4% | -$119.2M -12.9% | -$105.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | -186.5% +180.2pp | -366.6% -297.2pp | -69.5% +106.4pp | -175.9% -5.3pp | -170.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$22 +24.0% | -$30 -66.3% | -$18 +24.3% | -$24 -2.6% | -$23 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$22 +24.0% | -$30 -66.3% | -$18 +24.3% | -$24 -2.6% | -$23 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $8.5M +10.6% | $7.7M +27.7% | $6.0M +18.6% | $5.1M +10.0% | $4.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $8.5M +10.6% | $7.7M +27.7% | $6.0M +18.6% | $5.1M +10.0% | $4.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$80.98M
Precision BioSciences, Inc.
NASDAQ:DTIL
$78.25M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$61.36M
Metagenomi, Inc. Common Stock
MGX
$45.18M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does STRO generate?
Sutro Biopharma, Inc. (STRO) reported $102.48M of revenue in fiscal 2025.
Is STRO profitable?
Sutro Biopharma, Inc. (STRO) reported -$191,086,000.00 of net income, with a net margin of -186.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.